Description: Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients.
Home Page: www.fortebiorx.com
FBRX Technical Analysis
3060 Pegasus Park Drive
Dallas,
TX
75247
United States
Phone:
310 618 6994
Officers
| Name | Title |
|---|---|
| Dr. Paul A. Wagner Ph.D. | CEO & Chairman |
| Mr. Antony A. Riley CPA | Chief Financial Officer |
| Dr. Hubert C. Chen M.D. | Pres & Chief Scientific Officer |
| Mr. Christopher Roenfeldt | Chief Operating Officer |
| Mr. Steven Ruhl | Chief Technical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4854 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-04-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |